Teleflex Subsidiary Faces Federal False Claims Investigation

Urology device developer NeoTract, which Teleflex purchased in 2017, is now under scrutiny for potential FCA violations. 

MAPLE GROVE, MN/USA - MARCH 17, 2018: Teleflex and Vascular Solutions corporate building. Teleflex is a provider of specialty medical devices for a range of procedures in critical care and surgery. - Image

The US Department of Justice is investigating Teleflex Medical subsidiary NeoTract, Inc. for potential False Claims Act (FCA) violations, the company revealed in a quarterly report filed 30 July.

In March, the DOJ asked Pennsylvania-based device company Teleflex for documents and information related to a single NeoTract customer, with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Medtech Insight

Investors Urged To Prioritize Patient Engagement To Ensure Clients’ Products Succeed

 

To succeed in medtech, investors must focus on patient outcomes. Gilde Healthcare says involving patients boosts product effectiveness, access and market success — making it a smart strategy in today’s strained healthcare systems.

Corify Care, Mayo Clinic Join Forces To Advance AI-Driven Global Cardiac Mapping Platform

 
• By 

Corify Care’s CEO said the company aims to submit its 510(k) application to the US FDA by year-end, targeting market clearance in 2026. The company hopes its collaboration with the Mayo Clinic will help speed adoption of ACORYS, a noninvasive mapping technology for use in complex cardiac ablations.

European Hospital Products Sourced Through ‘System That Rewards Exploitation,’ Watchdog Finds

 
• By 

While European sustainability directives CSDDD and CSRD are still in the process of adoption, environmental group Swedwatch claims the EU's procurement framework is devoid of accountability.